Role of markErs in the progreSsion of dIabeteS in Obese paTIeNts

Obese Patients Clinical Trial

— RESISTIN  

Official title:

Role of Some Markers in the Progression of Diabetes in Obese Patients: a 8-year Observational Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02934737
• Other study ID #: 20160004418
• Status: Completed
• Start date: October 2016
• Est. completion date: November 2018

Study information

• Verified date: November 2020
• Source: University of Pavia
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Obese patients will be enrolled from 2006 to 2014. The progression of diabetes mellitus will be observed (if any). Anthropometric and biochemical parameters will be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1000
• Est. completion date: November 2018
• Est. primary completion date: November 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Obesity (body mass index >/= 30 Kg/m2
• Normal blood glucose (glycemia < 100 mg/dl)

Exclusion Criteria:

• No exclusion criteria

Related Conditions & MeSH terms

• Obese Patients
• Obesity

Intervention

Other:
• Progression of diabetes

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Pavia

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression of diabetes	evaluation of glycemia during 8 years	8 years
Primary	Anthropometric parameters	Weight	8 years
Primary	Anthropometric parameters	Waist circumference; hip circumference; abdominal circumference	8 years
Primary	Markers of progression of diabetes	Adiponectin	8 years
Primary	Markers of progression of diabetes	Resistin	8 years